a b s t r a c t
The National Technical Advisory Group on Immunisation in India (NTAGI) fulfils a need for informing decision-making concerning the introduction of new vaccines and strengthening the Universal Immunisation Programme (UIP). The role and membership of NTAGI have expanded over the years in tune with the emerging needs and priorities of the Government of India. Current challenges include institutionalizing mechanisms to follow-up and monitor recommendations, to support research needs to fill information gaps, and to provide technical assistance for monitoring and periodically reviewing the UIP.
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Description and background
India adopted the Expanded Programme on Immunisation (EPI) in 1978, targeting 80% coverage of infants with Bacillus CalmetteGuérin, diphtheria, tetanus and pertussis vaccine, oral polio vaccine and typhoid-paratyphoid (whole cell, killed) vaccine. EPI was revised as the Universal Immunisation Programme (UIP) during [1985] [1986] [1987] [1988] [1989] [1990] , targeting 100% coverage; also typhoid-paratyphoid vaccine was dropped and measles vaccine was added. Tetanus toxoid vaccination of pregnant women was part of EPI and was retained in UIP.
The UIP is managed by two senior officers (Deputy and Assistant Commissioners) in the Immunisation Division of the Department of Family Welfare (DFW) under the Ministry of Health and Family Welfare (MoHFW) of the Government of India (GoI). The functional responsibility is shared between GoI and State Governments: GoI provides funds, policy formulation, training of staff, cold chain support and procurement and supply of vaccines and injection equipment while the States are responsible for the implementation of the program.
Earlier, there was no mechanism established within EPI/UIP for regular technical reviews. When technical inputs were required, ad hoc consultations with experts (identified on the basis of issues needing to be discussed) were undertaken. In 1985, measles vaccine was introduced as recommended by the Planning Com- One independent expert is mandated to function as Co-chair of the NTAGI.
The NTAGI is essentially a standing committee under the DFW in the MoHFW. As a specially established committee its official administrative position and status within the GoI is unclear, except that it was created by a formal Office Order from MoHFW. The current membership and Terms of Reference (TOR) of the initial NTAGI (2001) are detailed in Tables 1 and 2 . While nongovernment members are paid expenses to attend meetings, no remuneration is paid to government employees. So far no requirement for members to declare actual or potential conflicts of interest has been defined. However, members have been selected on the basis of a reputation for integrity in addition to expertise. Industry representatives may be invited to present data but they do not participate in other discussions. The development of a tool to ensure lack of, or to document any specific, conflict of interests is being considered for the future.
Operation of the NTAGI
The first meeting of the NTAGI was on 19 December 2001 with the following objectives:
1. Identification of reasons for declining immunisation coverage. 2. Involvement of the private sector to improve coverage levels. 3. Plans for expansion of the cold chain system.
Meeting schedules and format
In its early years the NTAGI met infrequently, but currently it meets more often (see below). The Immunisation Division acts as the Secretariat for scheduling meetings, preparing minutes and taking follow-up actions. The meeting agenda is based on the needs of the Immunisation Division as well as requests from the States. Meetings are "close-door" with additional observers attending by invitation only. However, the NTAGI has the ability to invite or coopt experts in specific fields according to need and the topics to be discussed. Manufacturers of vaccines do not play any role in NTAGI but have been invited on occasion. The decisions (resolutions) and recommendations of the NTAGI are reached by general agreement among members and Chair and to date there has been no need for members to vote.
On an ad hoc basis, NTAGI sub-groups and Expert Advisory Groups (outside NTAGI) are constituted through the Secretariat to address specific issues and to submit their summary assessments, suggestions and recommendations. In addition, the existing disease-specific working groups on measles and polio established through 'Partner Networks' (WHO, UNICEF, and other bilateral/international agencies) may forward their recommendations to the NTAGI for consideration.
For recommendations regarding the introduction of a new vaccine into the UIP, the NTAGI may directly make resolutions, or assign the task to a Sub-group to bring its proposals to the NTAGI meeting. The decision-making process is based on disease epidemiology, disease burden, cost-effectiveness analyses and priority of vaccine introduction related to other public health interventions. When data are inadequate, the opinions of experts and the collective wisdom of the members may be applied. A number of important interventions, namely introduction of vaccines against Japanese encephalitis, hepatitis B, rubella (in combination with a second opportunity for measles vaccine, as measles rubella vaccine) and Haemophilus influenzae type b (as a combination pentavalent vaccine) and introduction of autodisable syringes in the UIP, were recommended by the NTAGI and have been accepted by the MoHFW [2] .
Evolution of NTAGI

Since its formation in
More recently the NTAGI has made extensive deliberations on several issues-development of a Multi-Year Strategic Plan for the UIP (GoI, 2002 (GoI, -2007 , the pros and cons of introduction of rotavirus and pneumococcal vaccines, enhanced measles control activities, the safety of thiomersal in vaccines, introduction of vaccine vial monitors on all vaccine vials, review of the human resource needs for immunisation at GoI and State levels and the re-engineering of the UIP as a system. For several issues the NTAGI has made Table 2 Major roles and terms of reference of the National Technical Advisory Group on Immunisation in India.
Major roles
To be an advisory body to assist the Government of India in developing a nation-wide policy framework for vaccines and immunisation To prioritize immunisation activities and set attainable targets Identify critical gaps in policy and programme and identify studies, assessment and research areas to be addressed To review periodic assessment of the national immunisation programme, including immunisation performance and disease incidence
Terms of reference Identify reasons for the decline in immunisation coverage levels, identify bottlenecks and suggest measures to revitalize the routine immunisation activities Establish criteria for ensuring a cost effective expansion/renewal plan for the cold chain Set up norms for periodic evaluation of the immunisation programme (e.g., frequency surveys, methodology to be adopted, and mechanism for data dissemination) Examine the current status of surveillance under the Reproductive and Child Health Programme and suggest mechanism for integrating the National Polio Surveillance Project network with the existing surveillance system once the polio is eradicated Firm up guideline for epidemic/outbreak control measures for vaccine-preventable diseases Establish standards and criteria for introduction of new vaccines under the Universal Immunisation Programme Guide policy for introduction of injection safety technology into the immunisation programme Suggest innovative strategies for introducing demand generation strategies in the programme Examine the role of private sector vis-a-vis immunisation and suggest measures for a more effective programme with private sector partnership Identify strategies, which would be required under special circumstances for instance (a) in under served areas like urban slums and tribal areas (b) immunisation during natural calamities Identify areas that need research studies including cost effectiveness analysis, burden of diseases studies, operations research, etc., and suggest modalities for conducting the same Suggest mechanisms and modalities for improving the vaccine quality assurance through the National Regulatory Authority (Drug Controller General of India) Examine the need for decentralization of programme implementation and suggest the degree and modalities for affecting the same specific recommendations, many of which have been acted on by the MoHFW. On some issues, the recommendations are still being considered.
Over the years, the role of the NTAGI (and consequently the membership) has evolved to meet the changing requirements at the national level. Other issues pertaining to immunisation have also been taken up for ongoing discussions such as improving coverage and access, promoting vaccine security, monitoring of adverse events following vaccinations, vaccines beyond childhood (like human papilloma virus, seasonal influenza and meningitis vaccines), public-private partnerships in the UIP, and measuring and monitoring the impact of immunisations. Currently, the minutes and recommendations (http://mohfw.nic.in/dofw%20website/june.pdf) of the NTAGI are published on the MoHFW website (http://mohfw. nic.in/dofw%20website/dofw.htm), to promote transparency and facilitate access to everyone. At the last meeting of the NTAGI it was resolved to increase the frequency of meetings to twice annually initially, progressing to meeting every quarter.
Future directions and challenges
Recognizing the need to strengthen the functioning of the NTAGI, a number of issues have been proposed. The need for regular meetings of the NTAGI has been clear. Earlier meetings were announced on an ad hoc basis but in the future meetings are to be pre-scheduled. This will help to strengthen the NTAGI as an institution and to allow better monitoring of the implementation of recommendations. To achieve these goals the NTAGI has a critical need for full-time support services to provide a secretariat, as well as technical assistance for data review and developing norms and standards. A mechanism and funding for generating data (e.g., disease burden, vaccine efficacy, and cost effective studies) are needed to support the NTAGI's decision-making and recommendations. Since health personnel are the backbone of the immunisation program, there is a critical need for the NTAGI to widen its scope to include human resource issues in its agenda. Similarly, the expertise of the NTAGI may be used to monitor the progress of the UIP as well as to deliberate and provide recommendations on other important issues for strengthening childhood immunisation like improving access and coverage; optimizing utilization of resources; strengthening monitoring and supervision; reducing immunisation drop out rates by tracking children through full immunisation; and strengthening the surveillance of vaccine-preventable diseases and adverse events following immunisation.
Conclusion
The NTAGI has evolved from an ad hoc decision-making process to one that is transparent, collective and systematic using the best available evidence for decision-making. However, wide gaps between the available and optimal evidence required have been noted. This has occurred in part because available evidence often comes from research that was not necessarily conducted to provide specific data to inform decisions such as on the choice of vaccines and their inclusion in the UIP. A more serious gap is the lack of quantitative data on the frequency of diseases or mortality from the GoI agencies concerned with disease control, such as the National Institute of Communicable Diseases and the Central Bureau of Health Intelligence.
Recently there has been debate in local medical journals regarding the Indian NTAGI recommendations, e.g., the recommendation for a phased introduction of the combination pentavalent vaccine. This is seen as a healthy trend. Major weaknesses in the UIP remain that affect its efficiency. These include: the time taken by national and state governments to implement NTAGI recommendations; lack of an institutional mechanism to follow-up and monitor recommendations; and differing perceptions about the respective roles and responsibilities of GoI, State Governments and other stakeholders. The lack of comprehensive data on disease burden and the lack of surveillance systems for vaccine-preventable diseases add to the difficulty that India has in achieving the full potential of its Immunisation Division.
